~~		图 -	PTO/SB/21 (09-04)		
	JUL 2 5 20	06 🥳)	Approved for use through 07/31/2006. OMB 0651-0031 open and trademark Office; U.S. DEPARTMENT OF COMMERCE open of information unless it displays a valid OMB control number.		
Under the Paper	work Reduction at of 1995, no per	Application Number	10/772,963 (Conf. #5299)		
OTRA	NSMITTAL	Filing Date	5 February 2004		
	265ORM	First Named Inventor	David P. BINGAMAN et al.		
JUL 25	Tano th	Art Unit	1617		
/Agg		Examiner Name	Hui, San Ming R.		
(to be used for all	spondence after initial filing)	Attorney Docket Number	2471 US		
Total Number of P	ages in This Submission				
	E	NCLOSURES (Check all 1	that apply) After Allowance Communication to TC		
Amendmer Afte Afte Afte Afte Afte Afte Afte Afte	e Attached nt/Reply er Final idavits/declaration(s) of Time Request bandonment Request n Disclosure Statement	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on CD emarks	Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): 10 References and Return Card.		
	SIGNATUE	RE OF APPLICANT, ATTO	PRNEY, OR AGENT		
Firm Name		Alcon Research			
Signature Jerus Mellus					
Printed name Teresa J. Schultz					
Date 2006 Reg. No.			Reg. No. 40,526		
CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:					
Signature		Barba	Date 30 luly 2006		
t	I	m 1 14-16	Date 20 July 2006		

OIPE

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Barbara McKenzie

Typed or printed name

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

TATES PATENT AND TRADEMARK OFFICE

In re Application of: David P. BINGAMAN et al.

Serial No: 10/77,963 (Conf. #5299)

Filed: 5 February 2004

Examiner: Hui, San Ming R.

Group Art Unit: 1617

FOR: FORMULATIONS OF GLUCOCORTICOIDS TO TREAT PATHOLOGIC OCULAR

ANGIOGENESIS

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. 1.56, 1.97, AND 1.98

Mail Stop Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. 1.56, 1.97, and 1.98, Applicants submit the patents, articles, and other information referenced in the specification as filed. The references are listed on the attached PTO Form 1449. Applicants are submitting copies of the foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2), copies of the U.S. patents are not enclosed.

Applicants request that the listed patents, articles, and other information be considered during prosecution of this application and that they appear among the "References Cited" on any patent issuing herefrom.

Respectfully submitted,

Registration No. 40,256

(817) 551-4231

Address for Correspondence: Alcon Research, Ltd. Attn: Teresa J. Schultz 6201 S. Freeway, Mail Code TB4-8 Fort Worth, TX 76134-2099 Attorney Docket No.: 2471 US

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEFARTIMENT OF THE PROPERTY OF THE PROP Under the Paperwork Reduction Act of 1995 Substitute for form 1449/PTO JUL 2 5 2006

INFORMATION DISCLOSU STATEMENT BY APPER

(Use as many sheets as necessary)

Complete it Known				
Application Number	10/772,963 (Conf. #5299)			
Filing Date	5 February 2004			
First Named Inventor	David P. BINGAMAN			
Art Unit	1617			
Examiner Name	Hui, San Ming R.			
Attorney Docket Number	2471 US	/		

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1A	Number-Kind Code ^{2 (ff known)} US- 5,371,078	12/06/1994	Clark et al.	
	1B	US- 5,646,136	07/08/1997	Petrow et al.	
	1C	US- 6,726,918	04/27/2004	Wong et al.	
	1D	US- 2004/0127472 A1	07/01/2004	Jerdan et al.	
	1E	^{US-} 2006/0074061 A1	04/06/2006	Bingaman et al.	
	1	US-			
		US-			
	_	US-			
	 	US-			
		US-			
	-	US-			
<u> </u>		US-			
i	1				

		FOREIGN	PATENT DOCL	IMENTS		-
Examiner Initials*	Cite	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	т6
illias		Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	MM-DD-YYYY			\vdash
	1F	WO 97/41844 A1		Alcon Laboratories, Inc.		-
	1G	WO 98/19649 A2 and A3	05/14/1998			┼┤
	11	WO 2004/0736708 A2 and A3	09/02/2004	Alcon, Inc.		-
	 					

		·
	Date	
Examiner	Considered	
Signature	00.110.00.00	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For USPTO Patent Documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the Inis collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Und	er the Paperwork Re	eduction Act	of 1995, no persons ar	e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Substitute for form 1449/PTO				Application Number	10/772,963 (Conf. #5299)	
INFO	RMATIO	N DIS	CLOSURE	Filing Date	5 February 2004	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	David P. BINGAMAN	
				Art Unit	1617	
			ecessary)	Examiner Name	Hui, San Ming R.	
Sheet	2	of	2	Attorney Docket Number	2471 US	

	000	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Examiner Initials*	Cite No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	2A	Jonas JB, et al., Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularization, J. Cataract Refract. Surg. 28: 2040-2041 (2002)	
-	2B	Karmel, Miriam, "AMD Under the Scope", AM ACADEMY OF OPHTHALMOLOGY	
	2C	National Institutes of Health (NIH), "A Novel, Preservative-Free Steroid Formulation for Use as an Anti-Inflammatory"	
	2D	Penn et al., The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity, IOVS, 42, 1, 282-289 (Jan 2001)	ļ
	2E	Regenera Limited, Investor update August 2004	
	2F		
	2G		
	2H		
	21		
	2J		

Evaminer	Date	ł
Examiner	Considered	
Signature		ii ti - if - th is conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.